Treatment of cancer

GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices

Retrieved on: 
Friday, July 23, 2021
Medicine, Clinical medicine, Medical physics, Health care, Brachytherapy, GenesisCare, Treatment of cancer

ATLANTA, July 23, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) announced today that GenesisCare , a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.

Key Points: 
  • ATLANTA, July 23, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) announced today that GenesisCare , a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.
  • The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers.
  • Flexitron is Elekta's high dose rate (HDR) afterloader, used in almost two-thirds of all brachytherapy centers worldwide in over 100 countries.
  • The latest version of Flexitron, introduced in 2020, sets itself apart from conventional brachytherapy devices through its design, ensuring efficient, safe and effective treatments with fewer manual steps.

Study of Cancer Patients and COVID-19 Highlights Health Disparities

Retrieved on: 
Thursday, July 22, 2021
Treatment of cancer, Oncology

Researchers who led the study, which was recently published in Cancer Reports , analyzed data from 146,702 adults diagnosed with cancer between 2015 and 2020.

Key Points: 
  • Researchers who led the study, which was recently published in Cancer Reports , analyzed data from 146,702 adults diagnosed with cancer between 2015 and 2020.
  • Among hospitalized patients, the most common admission diagnoses were similar for patients with active cancer (first diagnosed or received anticancer treatment within the last 12 months) and those with a history of cancer.
  • , medical oncologist at Henry Ford Cancer Institute and principal investigator of the study at Henry Ford.
  • Henry Fords not-for-profit health plan, Health Alliance Plan (HAP), provides health coverage for more than 540,000 people.

RefleXion Expands Commercial Reach With Sale to Texas Cancer Center

Retrieved on: 
Wednesday, July 21, 2021
Oncology, Health, Medical devices, Hospitals, Radiology, Pharmaceutical, Biotechnology, Oncology, Cancer research, Cancer, Treatment of cancer

RefleXion Medical, Inc ., a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) as a new modality that will one day treat all stages of cancer, today announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders , a free-standing cancer treatment center with 15 locations throughout northern Texas.

Key Points: 
  • RefleXion Medical, Inc ., a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) as a new modality that will one day treat all stages of cancer, today announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders , a free-standing cancer treatment center with 15 locations throughout northern Texas.
  • View the full release here: https://www.businesswire.com/news/home/20210721005043/en/
    RefleXion Medical announces the sale of its X1 machine to The Center for Cancer and Blood Disorders in Texas.
  • We have a long history of offering our patients the latest advances in cancer therapies, clinical trials and cancer research, and BgRT continues this convention.
  • We are gratified by the commitment and enthusiasm of the clinicians at The Center for Cancer and Blood Disorders for our RefleXion X1 platform, said Todd Powell , president and CEO at RefleXion.

Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021

Retrieved on: 
Wednesday, July 7, 2021
Treatment of cancer, Cancer

(Nasdaq: LIXT) (Lixte or the Company), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MoneyShow July Virtual Expo taking place July 13-15, 2021.

Key Points: 
  • (Nasdaq: LIXT) (Lixte or the Company), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MoneyShow July Virtual Expo taking place July 13-15, 2021.
  • Lixte Biotechnology Holdings, Inc. ( Nasdaq:LIXT )is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning.

PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer treatments, Virotherapy, Cancer immunotherapy, Antineoplastic drugs, Immunotherapy, Chemotherapy, Cancer, Treatment of cancer

In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.

Key Points: 
  • In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.
  • Tislelizumab has been approved in China for four solid tumor indications and regulatory decisions are pending for two additional indications.
  • We look forward to evaluating whether LYT-200 in combination with BeiGenes tislelizumab can improve outcomes for patients with metastatic solid tumors.
  • Under the terms of the agreement, PureTech will maintain control of the LYT-200 program, including global R&D and commercial rights.

DGAP-News: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Retrieved on: 
Tuesday, July 6, 2021
Immune system, Treatment of cancer, Immune checkpoint, Organ systems, Medical specialties, Clinical medicine, Heat Biologics, APN401, APEIRON Biologics AG, APN401, APEIRON BIOLOGICS AG

Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors

Key Points: 
  • Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors
    Vienna, Austria, 06 July 2021: APEIRON Biologics AG announced today the start of a Phase Ib clinical trial with its product candidate APN401 for the treatment of solid tumors.
  • The principle of cell therapy with APN401 by inhibiting the immune checkpoint Cbl-b aims at the patient's own immune cells.
  • The open-label, multi-center Phase Ib clinical trial is expected to enroll approximately 60 patients at multiple sites in Austria.
  • Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, says: "We are thrilled to be contributing a groundbreaking cancer treatment with this truly pioneering step in development of our APN401 cell therapy.

Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy

Retrieved on: 
Thursday, July 1, 2021
MEN, Medical devices, Infectious diseases, Science, Family, Genetics, Consumer, Clinical trials, FDA, Biotechnology, Health, Other Science, Research, Women, Pharmaceutical, Seniors, Oncology, KRAS, Drugs, Breakthrough therapy, Orphan drugs, Health, Cancer, LabCorp, Treatment of cancer, Lung cancer, Sotorasib

Every day, cancer patients across the country anxiously await test results that directly impact treatment decisions.

Key Points: 
  • Every day, cancer patients across the country anxiously await test results that directly impact treatment decisions.
  • The therapy and this indicated use of the test as a companion diagnostic received approval from the U.S. Food and Drug Administration (FDA) in late May 2021.
  • According to the American Cancer Society, in 2020, 10-12% of the 228,000 people diagnosed with lung cancer carry the G12C KRAS mutation.
  • During the last 25 years, Labcorp has played a significant role in launching hallmark testing options for the treatment of cancer.

Immunicom Presentation Defines Breakthrough Subtractive Therapy’s Role in “New Era” Cancer Care at LSI’s Annual Emerging MedTech Summit

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Treatment of cancer, Cancer, Zimmer Biomet Robotics

View the full release here: https://www.businesswire.com/news/home/20210623005765/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210623005765/en/
    Amir Jafri, Founder and CEO of Immunicom, discussing the potential advantages of Immunicoms subtractive treatment strategy, Immunopheresis, in contrast to standard of care treatments.
  • (Photo: Business Wire)
    Immunicoms presentation, A New Era in Cancer Treatment was given by Founder and CEO, Amir Jafri, who discussed the potential advantages of Immunicoms subtractive treatment strategy, ImmunopheresisTM, in contrast to standard of care cancer treatments.
  • Immunicom is pioneering the cancer industry with a new technology and conducting multiple global cancer trials using this new treatment modality.
  • The Emerging Medtech Summit successfully connects innovative medtech startups with active investors each year, further accelerating our mission to deliver life changing technologies to patients in need.

Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

Retrieved on: 
Wednesday, June 23, 2021
Tumors of the hematopoietic and lymphoid tissues, Cancer, Treatment of cancer

BEDMINSTER, N.J. and SINGAPORE, June 23, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced a collaboration agreement with the Agency for Science Technology and Researchs (A*STAR) Institute of Molecular and Cell Biology (IMCB)in Singapore to form a research laboratory.

Key Points: 
  • BEDMINSTER, N.J. and SINGAPORE, June 23, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced a collaboration agreement with the Agency for Science Technology and Researchs (A*STAR) Institute of Molecular and Cell Biology (IMCB)in Singapore to form a research laboratory.
  • The agreement marks Tessas second collaboration with IMCB, a research institute within A*STAR, Singapores lead government agency spearheading scientific discovery and innovation in the region.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Retrieved on: 
Thursday, June 17, 2021
Clinical medicine, Medicine, Health, Antineoplastic drugs, Cancer, Treatment of cancer, Breast cancer, Chemotherapy, Cachexia

TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.
  • The company plans to continue development of these drug candidates and continue testing with animal models while entering a drug regulatory development route for each indication.
  • The company has also recently announced a decision to enter the Melanoma and Breast Cancer markets with new drug development projects.
  • We now have four cancer treatment drug development projects for Colorectal Cancer (CRC), Melanoma, Breast Cancer and Prostate Cancer; one pre-cancer antitumor drug development project for the treatment of Adenomatous Polyps in collaboration with Digestix Bioscience Inc.; one palliative drug development project for the treatment of Cancer related Anorexia Cachexia Syndrome (CACS); and two early-stage drug discovery projects targeting Neurodegenerative and Mental Health diseases".